Skip to content

The healthtech industry is experiencing intense competition as companies race to develop software and artificial intelligence (AI) tools for clinical decision support, medical telemetry, robotic surgery, surgical navigation, medical imaging analysis, drug discovery, clinical trial management, and countless other medical applications. This competitive landscape is driving substantial investment and rapid innovation, with established medtech providers, disruptive startups, and well-funded tech giants all striving to integrate AI into the medical industry and patient experience. 

LINKS 

Read “Building a Future-Proof IP Strategy for AI in Medtech,” co-authored by David J. Dykeman, Andrew (A.J.) Tibbetts, and Samuel S. Stone, published by Medical Product Outsourcing. 

Tags: GT Boston, GT Insight, innovation, Innovation & Artificial Intelligence, Published Article
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of David J. Dykeman David J. Dykeman

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice

…

David Dykeman, who serves as Co-Managing Shareholder of Greenberg Traurig’s Boston office and co-chairs the firm’s global Life Sciences & Medical Technology Group, is a registered patent attorney with more than 22 years of experience in patent and intellectual property law. David’s practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology.

David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multi-national corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities.

An author of over 50 articles and a speaker at over 45 conferences on intellectual property law, David is the founding co-chair of the ABA’s Medical Devices Committee. He was honored as one of Boston’s “40 Under 40” innovative business leaders by the Boston Business Journal and was named to the “40 Medtech Innovators Under 40” list by Medical Device & Diagnostic Industry (MD+DI) Magazine. David has also been named one of the top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine, an “IP Star” by Managing IP magazine, a “Life Science Star” by LMG Life Sciences, and one of the World’s Leading IP Strategists in the IAM 300.

Read more about David J. Dykeman
Show more Show less
Photo of Andrew (A.J.) Tibbetts Andrew (A.J.) Tibbetts

Leveraging his technical proficiency and prior software engineering career, Andrew (A.J.) Tibbetts provides business-oriented IP legal counseling for software, AI and electronics-based technologies. His strategic approach incorporates open source practices and trade secret policies alongside patents, and he advises clients on licensing, enforcement,

…

Leveraging his technical proficiency and prior software engineering career, Andrew (A.J.) Tibbetts provides business-oriented IP legal counseling for software, AI and electronics-based technologies. His strategic approach incorporates open source practices and trade secret policies alongside patents, and he advises clients on licensing, enforcement, diligence, and defense against infringement accusations. A.J.’s patents have directly led to clients closing funding rounds, and software patents A.J. wrote for clients have survived PTAB invalidity challenges and been enforced against competitors. He co-authored influential amicus briefs cited favorably by the U.S. Supreme Court and Federal Circuit Court of Appeals relating to patentability of software.

A.J. counsels traditional software and electronics companies, including artificial intelligence and machine learning (AI/ML) across a variety of domains, networking/telecom/CDN, fintech (including market data and infrastructure), blockchain and distributed ledger tech, speech recognition, natural language processing, and more. As “software eats the world,” a growing number of companies look to A.J. for advice protecting new investments in software and data science, including life sciences, biopharma, medtech, medical devices, radiology, digital health, health care IT, and healthtech companies. A.J. advises a broad clientele, from multinational corporations to small enterprises, serves on the boards of MassMEDIC and HealthTech Build, as well as on a digital health advisory panel for MassBio.

Prior to his legal career, A.J. worked as a programmer for IBM/Lotus, contributing to the development of Lotus Notes. He also served for several years as the lead developer for a sales analytics tool, overseeing its end-to-end implementation, including planning, coding, documentation, testing, and roll-out.

Read more about Andrew (A.J.) TibbettsAndrew (A.J.)'s Linkedin Profile
Show more Show less
Photo of Samuel S. Stone Samuel S. Stone

Sam Stone focuses his practice on creating and implementing strategies to develop and enforce intellectual property portfolios. His patent counseling and portfolio development practice includes both domestic and international patents and opinion work on the topics of patentability, clearance, validity, and infringement. Sam’s…

Sam Stone focuses his practice on creating and implementing strategies to develop and enforce intellectual property portfolios. His patent counseling and portfolio development practice includes both domestic and international patents and opinion work on the topics of patentability, clearance, validity, and infringement. Sam’s patents have survived dozens of PTAB invalidity challenges, and have been licensed by some of the largest software and technology companies in the world. Sam also assists clients with IP due diligence in investment transactions, mergers and acquisitions, and initial public offerings (IPOs).

Sam counsels software and electronics companies operating in many industries, including autonomous vehicles and industrial automation, automated machine learning (AutoML), cybersecurity, biosensors, and high-performance computing. In addition, Sam advises technology and life science companies on strategies for protecting their investments in data science, artificial intelligence (AI), and machine learning (ML) in domains such as drug discovery, medical devices, medical imaging, agricultural technology, biomanufacturing, biological systems modeling, and ‘omics’ technologies.

Read more about Samuel S. StoneSamuel S.'s Linkedin Profile
Show more Show less
Related Posts
Litigation Blog
Think Before You Chat: Using AI for Legal Questions May Waive Privilege and Create Discovery Risks
April 19, 2026
AI and Policy Header
2026 Outlook: Artificial Intelligence
December 24, 2025
AI and Policy Header
Trump Administration Issues Executive Order on National AI Policy Framework
December 16, 2025